1-(2-phenoxyethyl)piperidin-4-one | 16771-91-8

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯酚醚
• 英文名称: 1-(2-phenoxyethyl)piperidin-4-one
• 英文别名: 1-(2-phenoxy-ethyl)-piperidin-4-one；1-(2-phenoxyethyl)-4-piperidone；1-<2-Phenoxyethyl>-piperidon-(4)
• CAS: 16771-91-8
• 化学式: C₁₃H₁₇NO₂
• mdl: MFCD11937181
• 分子量: 219.283
• InChiKey: SRCZVHKTSLILCC-UHFFFAOYSA-N

物化性质

• 沸点：
  366.4±27.0 °C(Predicted)
• 密度：
  1.096±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.4
• 重原子数：
  16
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.461
• 拓扑面积：
  29.5
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  1-(2-phenoxyethyl)piperidin-4-one 、 反苯环丙胺盐酸盐 以 1,2-二氯乙烷 为溶剂， 反应 6.0h， 以65%的产率得到1-(2-phenoxyethyl)-N-((trans)-2-phenylcyclopropyl)piperidin-4-amine
  参考文献：
  名称：

  LSD1 Inhibitors

  摘要：

  本发明涉及抑制LSD1活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。

  公开号：

  US20170183308A1
• 作为产物：
  描述：

  N-叔丁氧羰基-4-哌啶酮 在 盐酸 、 potassium carbonate 、 sodium sulfate 、 potassium iodide 作用下， 以 1,4-二氧六环 、 乙腈 为溶剂， 反应 14.5h， 生成 1-(2-phenoxyethyl)piperidin-4-one
  参考文献：
  名称：

  LSD1 Inhibitors

  摘要：

  本发明涉及抑制LSD1活性的化合物。具体而言，本发明涉及化合物、药物组合物和使用方法，例如使用本发明的化合物和药物组合物治疗癌症的方法。

  公开号：

  US20170183308A1

文献信息

• Therapeutic agents
  申请人：KNOLL Aktiengesellschaft

  公开号：US05760035A1

  公开（公告）日：1998-06-02

  Compounds of formula I ##STR1## and pharmaceutically acceptable salts thereof in which R.sub.1, R.sub.2 and R.sub.3 independently represent hydrogen, hydroxy, halo, alkyl or alkoxy; ALK.sup.1 represents a C.sub.2-6 alkylene chain optionally substituted by one or more C.sub.1-2 alkyl groups; Y represents a piperidine ring which is attached through nitrogen to ALK.sup.1 ; R.sub.4 represents hydrogen or a C.sub.1-4 alkyl group; the broken line in --- represents a bond, or is absent and the free valency on Y is taken up by hydrogen and the free valency on CR.sub.4 is taken up by hydrogen or a C.sub.1-4 alkyl group; ALK.sup.2 is absent or represents a C.sub.1-4 alkylene chain optionally substituted by one or more C.sub.1-2 alkyl groups; and R.sub.5 and R.sub.6 independently represent hydrogen, alkyl, phenyl, alkyl (optionally substituted) or R.sub.5 and R.sub.6 together with the nitrogen atom to which they are attached represent a saturated 3-7 membered heterocyclic ring (with a proviso); are disclosed which are antiinflammatory, antiallergic and immunomodulatory agents. Compositions containing these compounds and processes to prepare these compounds are also disclosed.

  化合物的化学式如下 ##STR1## 及其药用盐，其中 R.sub.1、R.sub.2 和 R.sub.3 独立地代表氢、羟基、卤素、烷基或烷氧基；ALK.sup.1 代表一个 C.sub.2-6 烷基链，可选择地被一个或多个 C.sub.1-2 烷基基团取代；Y 代表通过氮原子连接到 ALK.sup.1 的哌啶环；R.sub.4 代表氢或一个 C.sub.1-4 烷基基团；--- 中的虚线代表键，或者不存在，Y 上的自由价被氢取代，CR.sub.4 上的自由价被氢或一个 C.sub.1-4 烷基基团取代；ALK.sup.2 不存在或代表一个 C.sub.1-4 烷基链，可选择地被一个或多个 C.sub.1-2 烷基基团取代；R.sub.5 和 R.sub.6 独立地代表氢、烷基、苯基、烷基（可选择地取代）或 R.sub.5 和 R.sub.6 与它们连接的氮原子一起代表饱和的 3-7 成员杂环环（附带条件）；这些化合物是抗炎、抗过敏和免疫调节剂。还披露了含有这些化合物的组合物以及制备这些化合物的方法。
• 6,9-disubstituted 2-[trans-(4-aminocyclohexyl) amino] purines
  申请人：——

  公开号：US20030105098A1

  公开（公告）日：2003-06-05

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2- [转-（4-氨基环己基）]氨基嘌呤，其在抑制细胞周期依赖性激酶，特别是cdk-2方面具有用途。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• 6, 9-disubstituted 2-&lsqb;trans-(4-aminocyclohexyl)amino&rsqb; purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06479487B1

  公开（公告）日：2002-11-12

  The present invention provides novel compounds of the formula (I) wherein R is selected from the group consisting of R2, R2NH—, or R3R4N—R5- wherein R2 is selected from the group consisting of C9-C12 alkyl, Z is selected from the group consisting of phenyl, heterocycle, cycloalkyl, and naphthanlene; and M is selected from the group consisting of hydrogen, C1-C4 alkyl, and wherein each C9-C12 alkyl or Z is optionally substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of D, E, wherein each D is independently selected from the group consisting of trifluoromethyl, trifluoromethoxy, and C1-C4 alkoxy; each E is independently selected from the group consisting of Hal, OH, and C1-C8 alkyl; R3 and R4 are selected from the group consisting of hydrogen, C1-C4 alkyl and (CH2)y-phenyl, wherein y is an integer 0-8, with the proviso that R3 and R4 not both be hydrogen; R5 is C1-C8 alkylene; and R1 is selected from the group consisting of cyclopentyl, cyclopentenyl and isopropyl, and the pharmaceutically acceptable salts, optical isomers, and hydrates thereof, with the proviso that when R2 is the group wherein n is 1 or greater; R1 is isopropyl or cyclopentyl; R6 is hydrogen, C1-C4 alkyl, or (CH2)m-phenyl; and Z is phenyl, heterocycle, or cycloalkyl, that Z is substituted with 1 to 3 substituents, which may be the same or different, and which are selected from the group consisting of In addition, the present invention provides a method of inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明提供了公式(I)的新化合物，其中R选自R2、R2NH-或R3R4N-R5-组成的群，其中R2选自C9-C12烷基，Z选自苯基、杂环、环烷基和萘基；M选自氢、C1-C4烷基和其中每个C9-C12烷基或Z可选择地被1-3个取代基取代，这些取代基可以相同也可以不同，选自D、E组成的群，其中每个D独立地选自三氟甲基、三氟甲氧基和C1-C4烷氧基；每个E独立地选自卤素、羟基和C1-C8烷基；R3和R4选自氢、C1-C4烷基和(CH2)y-苯基，其中y是0-8的整数，但R3和R4不能同时为氢；R5是C1-C8烷基；R1选自环戊基、环戊烯基和异丙基，以及其药学上可接受的盐、光学异构体和水合物，但当R2为n为1或更大的基团时；R1为异丙基或环戊基；R6为氢、C1-C4烷基或( )m-苯基；Z为苯基、杂环或环烷基，但Z被1-3个取代基取代，这些取代基可以相同也可以不同，选自此外，本发明提供了一种抑制细胞周期依赖性激酶，特别是cdk-2的方法。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• 6,9-disubstituted 2-&lsqb;trans-(4-aminocyclohexyl)amino&rsqb; purines
  申请人：Aventis Pharmaceuticals Inc.

  公开号：US06642231B2

  公开（公告）日：2003-11-04

  The present invention comprises 6-9-Disubstituted 2-[trans-(4-aminocyclohexyl]aminopurines that are useful in inhibiting cyclin dependent kinases, particularly cdk-2. The present invention also provides a method of preventing apoptosis in neuronal cells and a method of inhibiting the development of neoplasms.

  本发明涉及6-9-二取代的2-[trans-(4-氨基环己基)氨基]嘌呤，其对抑制细胞周期依赖性激酶，特别是cdk-2具有用处。本发明还提供了一种预防神经细胞凋亡和抑制肿瘤发展的方法。
• LSD1 inhibitors
  申请人：Mirati Therapeutics, Inc.

  公开号：US10233152B2

  公开（公告）日：2019-03-19

  The present invention relates to compounds that inhibit LSD1 activity. In particular, the present invention relates to compounds, pharmaceutical compositions and methods of use, such as methods of treating cancer using the compounds and pharmaceutical compositions of the present invention.

  本发明涉及抑制 LSD1 活性的化合物。特别是，本发明涉及化合物、药物组合物和使用方法，例如使用本发明化合物和药物组合物治疗癌症的方法。